Folotyn (pralatrexate injection) 40 mg/2ml


Facts of Folotyn (pralatrexate injection) ?

  • Medicine Name: Folotyn
  • Generic Name: pralatrexate
  • Approval Date: September 24, 2009.
  • Company Name: Allos Therapeutics, Inc.
  • Available as (Form & Strength): Sterile, single-use vials containing pr alatrexate at a concentration of 20 mg/mL in the following presentations: – 20 mg of pralatrexate in 1 mL solution in a vial (20 mg / 1 mL) – 40 mg of pralatrexate in 2 mL solution in a vial (40 mg / 2 mL)

What are the indications and usage?

FOLOTYN is a folate analogue metabolic inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on overa ll response rate. Clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated.

How supplied/storage and handling ?

FOLOTYN is available in single-use cl ear glass vials containing pralatrexate at a concen tration of 20 mg/mL as a preservative-free, sterile, clear ye llow solution individually packaged for intravenous use.

Vials must be stored refrig erated at 2-8°C (36-46°F) ( see USP Controlled Cold Temper ature) in original carton to protect from light.

Folotyn® is the trade for the generic chemotherapy drug Pralatrexate. In some cases, health care professionals may use the generic name pralatrexate when referring to the trade name Folotyn®.

Drug type: Folotyn® is an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug. This medication is classified as an “antimetabolite.” – (For more detail, see “How this drug works,” below.)

What this drug is used for:

  • For the treatment of peripheral T-cell lymphoma (PTCL).

Note: If a drug has been approved for one use, physicians may elect to use this same drug for other problems if they believe it may be helpful.